Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Pediatric patients affected by mild-to-moderate distal subungual onychomycosis (DSO) or affected by white superficial onychomycosis (WSO), due to dermatophytes, will be treated topically with P-3058 nail solution according to the appropriate treatment schedule.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
2 Years to 17 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age between 2 to 17 years
Males and females
Clinical diagnosis of mild-to-moderate distal sub-ungual onychomycosis without spikes/dermatophytoma and without lunula involvement or white superficial onychomycosis.
Positive mycroscopy examination from the target nail at screening.
Positive culture for dermatophyte from the target nail at screening.
Patients with onychomycosis caused by yeasts or non-dermatophytes mould.
Patients with nail psoriasis.
Patients with nail changes due to eczema, lichen planus or alopecia areata.
Patients with one-hand two-foot syndrome.
Patients with immunodeficiency disorder or use of immune suppressive therapy 3 months prior to screening visit or need for it.
Use of systemic antifungal drugs in the 6 months prior to screening visit.
Use of topical nail antifungal drugs in the four weeks prior to screening visit.